Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...
Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predi ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
As competitor search engines surge on Google's AI obsession, Microsoft has a very, very rare opportunity to exploit the ...
In Meta's Q1 earnings call, Barclays analyst Ross Sandler asked Zuckerberg about the company's strategy for AI coding and "the recursive self-improvement loop." Zuckerberg replied that he thinks that ...
New Mercer research spoke to about 12,000 executives and found that they expect some serious organisational design changes ...
Zaya1-8B is a huge shift in LLMs, and the results are impressive.
Recursion Pharmaceuticals exceeded EPS expectations by 15.38%. The company reported a significant revenue shortfall, missing forecasts by 60.26%. Pre-market stock price fell 1.84% amid broader biotech ...
Good morning, everyone, and thank you for joining us. Since stepping into this role, I've been focused on a singular question: how do we harness the full power of AI to consistently and with urgency ...